Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 80Breast Neoplasms 39Neoplasms 6Neoplasm Metastasis 4Leiomyoma 2Infertility 2Breast Neoplasms, Male 2Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunction, Physiological 1Sarcopenia 1Salivary Gland Neoplasms 1Recurrence 1Primary Dysautonomias 1Patient Compliance 1Ovarian Neoplasms 1Osteoporosis 1Osteitis Deformans 1Lymphatic Metastasis 1Kidney Diseases 1Hypertension 1Hyperlipidemias 1Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer 1Hodgkin Disease 1Hereditary Sensory and Autonomic Neuropathies 1Hemorrhage 1Fallopian Tube Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Ovarian Epithelial 1Bulbo-Spinal Atrophy, X-Linked 1Advanced Prostate Cancer 1

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Castrate Sensitive Prostate Cancer × Goserelin × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡